论文部分内容阅读
目的 探讨P gp、TopoⅡ和GST π在大肠癌的表达情况及其临床意义。方法 运用免疫组织化学技术 (SP法 )检测P gp、TopoⅡ和GST π在 6 9例大肠癌中的表达情况。 结果 (1) 6 9例大肠癌中 ,P gp表达者 6 0 87% ,TopoⅡ表达者 5 9 42 % ,GST π表达者 79 71% ,P gp和GST π共同表达者 5 2 17%。 (2 )P gp在高分化腺癌中高表达 ,在低分化腺癌低表达 (P =0 0 2 6 )。 (3)单因素分析表明 ,P gp表达与大肠癌患者的生存期和不良预后有关。Cox回归分析表明 ,P gp表达、P gp和GST π共同表达与患者的生存率有关 ,TopoⅡ表达对患者有保护趋势。结论 实验表明 ,P gp、TopoⅡ和GST π等多因素联合作用是大肠癌多药耐药性的主要作用机制。对大肠癌患者进行此三项指标的测定 ,对于患者预后的估计和制定合理的化疗方案具有积极的指导意义
Objective To investigate the expression of P gp, Topo Ⅱ and GST π in colorectal carcinoma and its clinical significance. Methods Immunohistochemical technique (SP method) was used to detect the expression of P gp, Topo Ⅱ and GST π in 69 cases of colorectal cancer. Results (1) In 69 cases of colorectal carcinoma, the expression of Pgp was 60 87%, Topo II was 59 42%, GST π was 79 71%, P gp and GST π was 5 2 17%. (2) Pgp was overexpressed in well-differentiated adenocarcinoma and low in poorly differentiated adenocarcinoma (P = 0.0026). (3) Univariate analysis showed that the expression of P gp was related to the survival and poor prognosis of patients with colorectal cancer. Cox regression analysis showed that the expression of Pgp, Pgp and GST π co-expression with the survival rate of patients, Topo Ⅱ expression in patients with protection trends. Conclusion The experimental results show that the combined effect of P gp, Topo Ⅱ and GST π is the main mechanism of multidrug resistance in colorectal cancer. The determination of these three indicators in patients with colorectal cancer has a positive guiding significance for the estimation of the patient’s prognosis and the development of a rational chemotherapy regimen